Suprasma HFA solution

18 YEARS OLD AND ABOVE
Relief of acute bronchospasm:
Adults: 100 or 200 mcg.

Prevention of allergen or exercise-induced bronchospasm:
Adults: 200 mcg before challenge.

Chronic therapy:
Adults: up to 200 mcg four times daily.

0 TO 18 YEARS OLD
Relief of acute bronchospasm:
Children: 100 mcg, the dose may be increased to 200 mcg if required.

Prevention of allergen or exercise-induced bronchospasm:
Children: 100 mcg, the dose may be increased to 200 mcg if required.

Chronic therapy:
Children: up to 200 mcg four times daily.

ADMINISTRATION
Salbutamol inhaler is administered by the oral inhaled route only. Salbutamol has a duration of action of 4 to 6 hours in most patients. Increasing use of beta-2 agonists may be a sign of worsening asthma. On demand use of should not exceed four times daily. Reliance on such supplementary use or sudden increase in dose indicates deteriorating asthma.

Salbutamol is a selective beta-2 adrenoceptor agonist. At therapeutic doses it acts on the beta-2 adrenoceptors of bronchial muscle, with little or no action on the beta-1 adrenoceptors of heart. With its fast onset of action, it is particularly suitable or the management and prevention of attack is asthma.
Bronchodilators should not be the only or main treatment in patients with severe or unstable asthma. Severe asthma requires regular medical assessment or death may occur. Patients with severe asthma have constant symptoms and frequent exacerbations, with limited physical capacity, and PEF values below 60% predicted at baseline with greater than 30% variability, usually not returning entirely to normal after bronchodilator. These patients will require high dose inhaled (e.g. > 1 mg/day beclomethasone dipropionate) or oral dose corticosteroid therapy. Sudden worsening of symptoms may require increased corticosteroid dosage which should be administered under urgent medical supervision.
Salbutamol is particularly valuable as relief medication in mild, moderate or severe asthma, provided that reliance on it does not delay the introduction and use of regular inhaled corticosteroid therapy.